VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX
Delisted
VIRX was delisted on the 3rd of February, 2025.
69 hedge funds and large institutions have $62.4M invested in Viracta Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 23 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
4% less capital invested
Capital invested by funds: $65.2M → $62.4M (-$2.79M)
43% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 23
Holders
69
Holding in Top 10
1
Calls
$934K
Puts
$287K
Top Buyers
| 1 | +$1.15M | |
| 2 | +$764K | |
| 3 | +$529K | |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$105K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$87.9K |
Top Sellers
| 1 | -$1.88M | |
| 2 | -$1.53M | |
| 3 | -$582K | |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$408K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$296K |